Cas:54940-95-3 Nitrocaphane manufacturer & supplier

Chemical Name:Nitrocaphane

CAS.NO:54940-95-3

Synonyms:Nitrocaphane;At-1258;Phenylalanine,2-((bis(2-chloroethyl)amino)methyl)-5-nitro;2-((Bis(2-chloroethyl)amino)methyl)-5-nitrophenylalanine;3-[2-[[Bis(2-chloroethyl)amino]methyl]-5-nitrophenyl]-2-aminopropionic acid;(S)-2-Amino-3-(2-((bis(2-chloroethyl)amino)methyl)-5-nitrophenyl)propanoic acid

Molecular Formula:C₁₄H₁₉Cl₂N₃O₄

Molecular Weight:364.22400

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:475.2ºC at 760 mmHg

Density:1.392g/cm3

Index of Refraction:1.595

PSA:112.38000

Exact Mass:363.07500

LogP:3.05230

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Nitrocaphane chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(S)-2-Amino-3-(2-((bis(2-chloroethyl)amino)methyl)-5-nitrophenyl)propanoic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Nitrocaphane Use and application,(S)-2-Amino-3-(2-((bis(2-chloroethyl)amino)methyl)-5-nitrophenyl)propanoic acid technical grade,usp/ep/jp grade.

Related News: The April halt followed the discovery that ingredients from AstraZeneca’s (AZN.L) COVID-19 vaccine, also being produced at the plant at the time, contaminated a batch of J&J’s vaccine. AstraZeneca’s shot is no longer being made there. Nitrocaphane manufacturer The Darzalex-Rd regimen got its FDA go-ahead in transplant-ineligible patients in 2019 based on data from the same phase 3 MAIA trial showing it could pare down the risk of disease progression or death by 44% after a median follow-up of 28 months. Now, after 56.2 months of follow-up, over half of Darzalex patients were still alive without their disease worsening, a showing that’s again “unprecedented” for a front-line myeloma treatment, Tendler said. Nitrocaphane supplier The national airlines of Egypt, Qatar and Saudi Arabia have halted flights to and from China. Nitrocaphane vendor The national airlines of Egypt, Qatar and Saudi Arabia have halted flights to and from China. Nitrocaphane factory The Darzalex-Rd regimen got its FDA go-ahead in transplant-ineligible patients in 2019 based on data from the same phase 3 MAIA trial showing it could pare down the risk of disease progression or death by 44% after a median follow-up of 28 months. Now, after 56.2 months of follow-up, over half of Darzalex patients were still alive without their disease worsening, a showing that’s again “unprecedented” for a front-line myeloma treatment, Tendler said.